{"url_path":"/sec/bcax/8-k/2026-08-11/item-2-02","section_key":"item-2-02","section_title":"Item 2.02 Results of Operations and Financial Condition.","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-08-11","source_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-055500-index.html","accession_number":"0001628280-26-055500","cik":"0002023658","ticker":"BCAX","issuer_name":"Bicara Therapeutics Inc.","edgar_url":"https://www.sec.gov/Archives/edgar/data/2023658/0001628280-26-055500-index.html","primary_entity_key":"0002023658","primary_entity_name":"Bicara Therapeutics Inc."},"word_count":146,"has_tables":true,"body_markdown":"Item 2.02 - Results of Operations and Financial Condition.\n\nOn August 11, 2026, Bicara Therapeutics Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2026 and other business updates. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.\n\nThe information set forth under Item 2.02 and in Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing."}